Veracyte公司宣布,其用于预测复发性前列腺癌男性患者激素治疗获益的生物标志物的首个前瞻性验证数据将在ASTRO 2025大会上进行展示。
Veracyte公司宣布,其用于预测复发性前列腺癌男性患者激素治疗获益的生物标志物的首个前瞻性验证数据将在ASTRO 2025大会上进行展示。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.